Poolbeg Pharma’s Shares Plunge as It Enters Merger Talks with Hookipa Pharma
Poolbeg Pharma, a clinical-stage biopharmaceutical company led by experienced entrepreneur Cathal Friel, faced a significant downturn in its stock price on Thursday following the announcement of merger talks with Hookipa Pharma, a Nasdaq-listed peer undergoing major restructuring.
Merge Details and Market Impact
The proposed transaction involves an all-share merger structured as a reverse takeover, initially giving Poolbeg investors a 55% stake in the combined entity. Upon the completion of a planned $30 million equity raise, Poolbeg’s stake could be diluted to around 40%. This share deal caused Poolbeg’s shares to fall by 38% to 4.4 pence on AIM, the London junior stock market, reducing its market value to £22 million. Meanwhile, Hookipa’s shares saw only minor fluctuations on the New York exchange.
Background on Hookipa Pharma
Hookipa Pharma, chaired by Irish life sciences veteran Julie O’Neill, has faced significant challenges in 2023. The company underwent a series of senior management changes and announced several rounds of job cuts, reducing its workforce to below 20 from 180 at the start of the year. Despite raising over $70 million in share sales in 2023, Hookipa’s cash reserves dropped by almost 50% to $60 million by the end of September, contributing to a 76% decline in its stock.
Opportunities and Leadership
Industry experts believe that Poolbeg might leverage its experience to revitalize Hookipa. Upon merger completion, Poolbeg would be led by Friel, who would take on the role of executive chairman. Hookipa’s current CEO, Malte Peters, is expected to lead the combined organization, while Ian O’Connell will handle the financial aspects. The new entity plans to maintain Hookipa’s Nasdaq listing.
Product Pipeline and Focus
The combined company aims to create a diverse pipeline of potential treatments. Central to this strategy are Hookipa’s HB-700, a groundbreaking immunotherapy for cancers with limited treatment options, and Poolbeg’s POLB 001, a preventive therapy against adverse reactions to cancer immunotherapies. These advances signify the potential for significant advancements in oncology.
Poolbeg’s History and Entrepreneurial Background
Poolbeg Pharma, founded in 2021 through the spin-off of Hvivo, demonstrates Cathal Friel’s history of successful pharmaceutical mergers. Previous ventures include orchestrating the IPO of Open Orphan in 2019 and the merger of Fastnet Oil & Gas with Amryt Pharma in 2006. Amryt was eventually acquired by Chiesi Farmaceutici in 2023 for approximately $1.48 billion, highlighting Friel’s strategic acumen in the pharmaceutical sector.
Former Executives Join Poolbeg
Three prominent Amryt executives—David Allmond, John McEvoy, and Laura Maher—have recently joined Poolbeg, further strengthening the company’s leadership and operational capabilities.
Sign Up for the Latest Business News
- Subscribe to the Business Today newsletter to receive daily business news and analysis in your inbox.
- Enable Business push alerts to receive breaking news and insights directly on your mobile device.
- Follow The Irish Times on WhatsApp to stay updated with the latest business developments.
- Listen to our Inside Business podcast for in-depth analysis and expert interviews on current business trends.
Stay informed about the latest developments in the pharmaceutical industry by subscribing to our newsletters and following our social media channels. Share your thoughts on this merger and its implications for the pharmaceutical sector in the comments below.
